Skip Navigation
National Cancer Institute
National Cancer Institute U.S. National Institutes of Health National Cancer Institute
OverviewProgramsAccomplishmentsEvent ListingNews and HighlightsPublished Research

Fourth Annual NCI Alliance for Nanotechnology in Cancer Investigators' Meeting

October 20-22, 2009
Manhattan Beach, California

Dear Colleagues:

On behalf of the National Cancer Institute’s (NCI) Alliance for Nanotechnology in Cancer, we are pleased to invite you to the Fourth Annual NCI Alliance for Nanotechnology in Cancer Investigators’ Meeting, October 20-22, 2009, in Manhattan Beach, California. In keeping with our tradition of convening the annual meeting at the site of a Center of Cancer Nanotechnology Excellence (CCNE), this year we will host the event jointly with our host and CCNE colleagues from the California Institute of Technology and the University of California, Los Angeles.

The Alliance focuses on the development of translational technologies that can impact practical applications in the clinic. The program is revolutionary in its approach to delivering on these goals – it brings together a multidisciplinary community of oncologists, biologists, physical scientists, and engineers. The last few years have been rich in significant scientific advances, numerous high-profile papers and patents published, and new companies, focused on technology commercialization, founded. Thanks to your contributions, the overall achievements of the Alliance throughout the last 4 years have been outstanding. In recognition of this performance, the NCI Executive Committee and Board of Scientific Advisors have approved the 5-year re-issuance of the program (years 2010-2015) enabling the further exploration of oncological applications of nanotechnology. The upcoming annual PI meeting in Manhattan Beach, California, will continue to highlight scientific advances of the Alliance partners, foster collaborations and provide a venue for working group discussions. Keeping an eye on the future, we will also host a tutorial session to provide education and guidance to the next generation of young nanoscientists. Finally, clinical translation and technology commercialization will be addressed in a special translational session where successful Alliance spinoff companies will present their accomplishments.

We are looking forward to your participation in this important event.


Piotr Grodzinski, Ph.D.
Director, NCI Alliance for Nanotechnology in Cancer
National Cancer Institute


For additional information regarding logistics and registration, Alliance members should contact Dr. Krzysztof Ptak at (301) 496-1550.